Review of trans-atlantic cardiovascular best medical therapy guidelines - recommendations for asymptomatic carotid atherosclerosis

Current Vascular Pharmacology

Volumn 11, Issue 4, 2013, Pages 514-523

  Davies, Kerry J ^a   Thapar, Ankur ^a   Kasivisvanathan, Veeru ^a   Shalhoub, Joseph ^a   Davies, Alun H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Carotid stenosis; Guidelines; Medical therapy

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; SIMVASTATIN; TRIACYLGLYCEROL;

BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; META ANALYSIS (TOPIC); NICOTINE REPLACEMENT THERAPY; NONHUMAN; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; WEIGHT REDUCTION;

CAROTID ARTERY DISEASES; CAROTID STENOSIS; EVIDENCE-BASED MEDICINE; HUMANS; INTERNATIONALITY; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, MEDICAL; STROKE;

EID: 84882809364     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311040015     Document Type: Review

References (74)

1. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273: 1421-8.
2. Halliday A, Harrison M, Hayter E, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010; 376: 1074-84.
3. Madani A, Beletsky V, Tamayo A, Munoz C, Spence JD. High-risk asymptomatic carotid stenosis: ulceration on 3D ultrasound vs. TCD microemboli. Neurology 2011; 77: 744-50.
4. Goessens BM, Visseren FL, Kappelle LJ, Algra A, van der Graaf Y. Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. Stroke 2007; 38: 1470-5.
5. Abbott AL. Medical (non-surgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009; 40: e573-83.
6. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting vs. aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993-1003.
7. Hobson RW, 2nd, Weiss DG, Fields WS, et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group. N Engl J Med 1993; 328: 221-7.
8. de Weerd M, Greving JP, Hedblad B, et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010; 41: 1294-7.
9. Hingorani A, Hemingway H. How should we balance individual and population benefits of statins for preventing cardiovascular disease? BMJ 2011; 342: 312-315.
10. Bouri S, Thapar A, Shalhoub J, et al. Hypertension and the postcarotid endarterectomy cerebral hyperperfusion syndrome. Eur J Vasc Endovasc Surg 2011; 41: 229-37.
11. Engelter S, Lyrer P. Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database Syst Rev 2003; (3): CD001458.
12. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006; 32: 286-93.
13. Paraskevas KI, Veith FJ, Liapis CD, Mikhailidis DP. Perioperative/periprocedural effects of statin treatment for patients undergoing vascular surgery or endovascular procedures: an update. Curr Vasc Pharmacol 2012.
14. Nowaczenko M, Sarzynska-Dlugosz I, Czlonkowska A. Prevalence of carotid arteries atherosclerotic changes in ischemic stroke patients. Neurol Neurochir Pol 2003; 37: 27-36.
15. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl 5): v1-52.
16. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375-414.
17. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHAAANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Stroke; a journal of cerebral circulation 2011; 42: e464-540.
18. Ricotta JJ, Aburahma A, Ascher E, et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. J Vasc Surg 2011; 54: e1-31.
19. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 517-84.
20. Smith SC, Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73.
21. Liapis CD, Bell PF, Mikhailidis DP, et al. ESVS Guidelines: Section A--prevention in patients with carotid stenosis. Curr Vasc Pharmacol 2010; 8: 673-81.
22. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-10.
23. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-91.
24. National Cholesterol Education Program. ATP III Guidelines. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. 1993.
25. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-85.
26. Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag 2007; 3: 783-95.
27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
28. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
29. Counseling and interventions to prevent tobacco use and tobaccocaused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009; 150: 551-5.
30. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-62.
31. Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Coch Database Syst Rev 2011; (12): CD003186.
32. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
33. Makris GC, Lavida A, Nicolaides AN, Geroulakos G. The effect of statins on carotid plaque morphology: a LDL-associated action or one more pleiotropic effect of statins? Atherosclerosis 2010; 213: 8-20.
34. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
35. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453-63.
36. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2004; 117: 596-606.
37. Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev 2009; (3): CD002091.
38. De Caterina R, Scarano M, Marfisi R, et al. Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010; 55: 198-211.
39. Kang S, Wu Y, Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 2004; 177: 433-42.
40. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dosespecific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003; 4: 18.
41. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
42. Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2008; 39: 3297-302.
43. Amarenco P, Goldstein LB, Messig M, et al. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke 2009; 40: 2486-92.
44. Amarenco P, Goldstein LB, Sillesen H, et al. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2010; 41: 426-30.
45. Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol 2011; 68: 1245-51.
46. Bell KJ, Kirby A, Hayen A, Irwig L, Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ 2011; 342: d12.
47. Paraskevas KI, Veith FJ, Mikhailidis DP. Carotid intima-media thickness and ezetimibe: the end of a misunderstanding? Curr Vasc Pharmacol 2011; 9: 381-4.
48. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
49. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
50. A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
51. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
52. Kronish IM, Rieckmann N, Shimbo D, Burg M, Davidson KW. Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. Am J Cardiol 2010; 106: 1090-4.
53. NICE. CG127: NICE Guideline http://guidance.nice.org.uk/CG127?NICEGuidance/pdf/English. 2011 April 2012].
54. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131-41.
55. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12.
56. Smith SC, Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011; 58: 2432-46.
57. Rodriguez BL, D'Agostino R, Abbott RD, et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. Stroke 2002; 33: 230-6.
58. Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115(Pt 2): 242-9.
59. NICE. Costing report: brief interventions and referral for smoking cessation in primary care and other settings PHI001 http://www.nice.org.uk/ [PHI001. 2006 April 2012].
60. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 135-44.
61. Kabbinavar F, Irl C, Zurlo A, Hurwitz H. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 2008; 75: 215-23.
62. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005; 82(Suppl): 222S-225S.
63. The Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. BMJ 2011; doi:10.1016/S0140-6736(11)60105-0.
64. Walker SP, Rimm EB, Ascherio A, et al. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 1996; 144: 1143-50.
65. Despres JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511.
66. Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277: 1539-45.
67. Chang HY, Hu YW, Yue CS, et al. Effect of potassium-enriched salt on cardiovascular mortality and medical expenses of elderly men. Am J Clin Nutr 2006; 83: 1289-96.
68. Spence JD, Tamayo A, Lownie SP, Ng WP, Ferguson GG. Absence of microemboli on transcranial Doppler identifies low-risk patients with asymptomatic carotid stenosis. Stroke 2005; 36: 2373-8.
69. Spence JD, Coates V, Li H, et al. Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol 2010; 67: 180-6.
70. Spence J, Hackam DG. Treating arteries instead of risk factors: a paradigm change in management of atherosclerosis. Stroke 2010; 41: E488-E488.
71. Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin vs. aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9: 489-97.
72. Sharma A, Kasim M, Joshi PH, et al. Abnormal lipoprotein(a) levels predict coronary artery calcification in Southeast Asians but not in Caucasians: use of non-invasive imaging for evaluation of an emerging risk factor. J Cardiovasc Transl Res 2011; 4: 470-6.
73. Paraskevas KI, Hamilton G, Mikhailidis DP. Clinical significance of carotid bruits: an innocent finding or a useful warning sign? Neurol Res 2008; 30: 523-30.
74. Pickett CA, Jackson JL, Hemann BA, Atwood JE. Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis. Lancet 2008; 371: 1587-94.